BioWorld

July 27, 2007

Hydra Lands Potential $195M Deal With Pfizer On Pain Drugs

Hydra Biosciences Inc. licensed rights to its TRPV3 antagonist program to Pfizer Inc. in a deal valued at up to $195 million. (BioWorld Today) Read More

Exelixis Moving Forward On XL647 After GSK Declines

ATP Sense Channels Link Spinal Cord Injury, Stroke, Diabetes

Aspreva Restructures, Plans To Look Beyond CellCept

Revlimid Sales Drive Celgene's Second-Quarter Revenue Growth

Other News To Note

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for June 10, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for June 9, 2026

3D rendering of β2-Adrenergic receptor GPCR protein molecule embedded in lipid bilayer membrane.

Skape Bio unlocks GPCR targets with de novo-designed miniproteins

BioWorld

Modulating G protein-coupled receptors (GPCRs) is one of the major challenges in biomedicine. These are flexible proteins with small, deep binding pockets. The...

Wuxi Apptec insists it’s ‘not a Chinese military company’

BioWorld

Wuxi Apptec isn’t going down without a fight after the U.S. Department of Defense added it to the Section 1260H list June 8 as a designated “Chinese military...

Antares Therapeutics divulges new CDK2/cyclin E1 inhibitors

BioWorld Science

Antares Therapeutics Inc. has reported new CDK2/cyclin E1 inhibitors potentially useful for the treatment of cancer.